March 20 (Reuters) - XTL Biopharmaceuticals Ltd said it signed a $108 million deal licensing its pre- clinical hepatitis C program to San-Francisco based private biotechnology firm Presidio ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback